Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety and tolerability of a combination
of bedaquiline, linezolid, cycloserine, clofazimine and pyrazinamide treatments guided by PZA
sensitivity for 24 to 36 weeks in subjects with fluoroquinolone-resistant MDR-TB .